Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a calf thymus extract characterised by Allan Goldstein's laboratory at George Washington University in the 1970s. It is produced naturally in the thymus gland and plays a foundational role in T-cell maturation, innate immune activation, and the cytokine signalling networks that govern adaptive immunity. Unlike most research peptides discussed in optimisation circles, Thymosin Alpha-1 has a substantial clinical trial database and has been approved under the trade name Zadaxin in more than 40 countries.
Key Takeaways
- —Thymosin Alpha-1 (Tα1) is a 28-aa endogenous thymic peptide commercially available as Zadaxin, approved in 40+ countries and holding FDA Orphan Drug status for multiple conditions.
- —A meta-analysis of 12 randomised controlled trials in chronic hepatitis B found Tα1 combination therapy produced 2.4× higher seroconversion rates versus interferon monotherapy (Zhang et al., World Journal of Gastroenterology, 2005).
- —Three RCTs in severe COVID-19 patients (2020–2021) showed Tα1 significantly reduced 28-day mortality and ICU admission rates compared to standard care.
- —Standard clinical dose is 1.6 mg subcutaneous twice weekly — the same protocol used in the hepatitis B and malignant melanoma trials.
Tα1 is the N-terminal 28-amino-acid peptide of prothymosin alpha, a nuclear protein expressed in virtually all mammalian cells. The thymus gland produces Tα1 as part of the machinery that educates naive T-cells — differentiating CD4+ helper and CD8+ cytotoxic T-cells, and establishing tolerance to self-antigens.
The immunostimulatory mechanisms are multifactorial:
Toll-Like Receptor (TLR) signalling: Tα1 acts as a TLR2 and TLR9 agonist, activating dendritic cells and triggering the innate immune cascade. TLR9 activation in particular drives type I interferon production — the front-line antiviral response — which is why Tα1 shows efficacy in viral infections.
T-cell differentiation and maturation: Tα1 promotes differentiation of immature thymocytes into functional CD3+ T-cells, upregulates surface expression of T-cell markers (CD2, CD3, CD4, CD8), and enhances MHC class I expression on tumour cells — a key step in making malignant cells visible to cytotoxic T-lymphocytes.
NK cell activation: Natural killer cell cytotoxic activity is increased by Tα1 treatment. This contributes to both anti-viral and anti-tumour effects.
Cytokine balance modulation: Tα1 promotes a Th1-polarised immune response (IL-2, IFN-γ, TNF-α) while modulating Th2 and Th17 responses. In immunocompromised patients, this shifts the balance toward effective viral clearance.
Thymosin Alpha-1 activates Toll-Like Receptors 2 and 9 on dendritic cells and macrophages, triggering type I interferon production and promoting Th1 immune polarisation. This mechanism explains clinical efficacy across viral infections (hepatitis B, COVID-19) and malignant conditions where T-cell-mediated cytotoxicity is insufficient. Standard clinical dose is 1.6 mg subcutaneous twice weekly (Zadaxin protocol).
The hepatitis B data for Tα1 is the most clinically robust and externally validated in the literature. A 2005 meta-analysis (Zhang et al., World Journal of Gastroenterology) pooled 12 randomised controlled trials:
A Cochrane-style systematic review (Li et al., 2015) covering 26 trials and 2,256 patients confirmed these findings with a pooled HBeAg seroconversion OR of 2.77 (95% CI: 2.05–3.76) for combination therapy versus interferon alone.
The hepatitis B data is unusually strong for a research peptide. Twelve RCTs covering thousands of patients is a clinical evidence base that most compounds discussed in peptide research circles will never approach. This evidence quality is what makes Tα1 different from aspirational longevity peptides — it has demonstrated clinical utility in a hard endpoint (viral clearance) in prospective, randomised, controlled conditions.
Three RCTs published in 2020–2021 investigated Tα1 in severe COVID-19:
Liu et al. (2020) — 120 severe COVID-19 patients; Tα1 group had significantly lower 28-day mortality (11.1% vs. 30.0%), faster lymphocyte recovery, and lower inflammatory markers (IL-6, CRP) versus standard care.
Shi et al. (2021) — Tα1 reduced ICU admission and the need for mechanical ventilation in hospitalised patients. Lymphocyte count recovery was markedly faster.
Wu et al. (2021) — Multicentre study; Tα1 adjunct therapy reduced severe COVID progression rate (28.4% vs. 51.4% in controls).
The mechanistic logic is coherent: COVID-19 severe disease involves lymphopenia, impaired innate immune response, and cytokine dysregulation — all areas where Tα1 has established activity. This is not a speculative extrapolation.
The Zadaxin clinical dosing protocol — used across the hepatitis B, malignant melanoma, and COVID-19 trials — is standardised:
| Parameter | Value |
|---|---|
| Dose | 1.6 mg per injection |
| Route | Subcutaneous |
| Frequency | Twice weekly |
| Duration | 6 months (hepatitis B); variable for other indications |
| Reconstitution | Supplied pre-mixed as Zadaxin; research grade requires bacteriostatic water |
For immune optimisation protocols outside the clinical trial context, practitioners typically use 1.6 mg SC twice weekly for 4–12 weeks, with cycles repeated 1–2× per year. Some protocols use lower doses (0.8–1.6 mg) 1–3× per week for shorter acute cycles.
Thymosin Alpha-1 has one of the cleanest safety profiles in the peptide research space, driven by its status as an endogenous thymic peptide and its extensive clinical use across 40+ countries under Zadaxin. Published adverse event data from trials covering thousands of patients reports:
Thymosin Alpha-1's 40-country clinical approval record and Orphan Drug status make it one of the most evidence-backed peptides in this space — but that doesn't mean every source selling it is reliable. The Next Pep peptide library covers the full 28-aa thymic peptide profile: Th1/Th2 immune modulation mechanism, Zadaxin regulatory status, the hepatitis B meta-analysis data, and the COVID-19 RCT mortality findings — all in one verified reference.
Use the comparison tool to put Thymosin Alpha-1 alongside BPC-157 or other immune-modulating peptides you're researching, side-by-side across mechanism, evidence quality, and regulatory status. The dosing calculator handles reconstitution for the standard 1.6 mg SC protocol or any custom dose: enter your vial concentration and it returns exact draw volume and syringe units.
Zadaxin is the trade name for synthetic Thymosin Alpha-1 manufactured by SciClone Pharmaceuticals. It is the same 28-amino-acid peptide as research-grade Tα1. Zadaxin is approved in 40+ countries for chronic hepatitis B and is used off-label for hepatitis C, malignant melanoma adjuvant therapy, and more recently as an immunomodulator in severe infections. It holds FDA Orphan Drug status.
Tα1's primary effect is immune normalisation and Th1 polarisation, not non-specific immune "boosting." In immunocompromised patients (viral infection, cancer chemotherapy, severe illness) it restores depleted T-cell function. In immunocompetent subjects, the effect is more modulatory — improving immune response quality without overactivation. It doesn't function like a simple stimulant.
The clinical rationale is strongest for viral and intracellular bacterial infections where T-cell-mediated immunity is critical. Published data covers hepatitis B, hepatitis C (adjuvant to interferon), respiratory viral infections, and sepsis. The mechanistic case for recurring herpes, EBV reactivation, and Lyme co-infections is plausible but lacks the same RCT-level evidence.
These compounds address completely different biological systems. Tα1 is primarily an immune modulator — its effects are at the level of T-cell differentiation, dendritic cell activation, and viral clearance. BPC-157 is a mucosal healing peptide operating through VEGFR2–eNOS angiogenesis and FAK-paxillin cell migration pathways — its effects are in tissue repair, gut healing, and tendon regeneration. They can be used together without mechanistic interference.
This article is for research and educational purposes only. Thymosin Alpha-1 is not FDA-approved for general use in the United States. Zadaxin holds Orphan Drug status for specific indications. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.